The 2023 Emerging Pharma Leaders share with the Pharmaceutical Executive editors what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. (This is the video podcast of the Pharm Exec Podcast episode!)
Each year, Pharmaceutical Executive recognizes up-and-coming leaders who are vital to the future of the pharmaceutical and biotech industry in the Emerging Pharma Leaders (EPL) Awards. Nominations are judged by three members of the Editorial Advisory Board as well as a former EPL representative. This year, five winners were selected, all of whom had incredible journeys to share with the editorial team.
The Pharm Exec team would like to congratulate the 2023 Emerging Pharma Leaders:
In this episode of the Pharm Exec Podcast, Meg Rivers, managing editor, and the editorial team speak with the EPL winners, asking each about:
2023 Emerging Pharma Leaders: Changing Lives One Story, One Therapeutic at a Time
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.